Biohaven Announces Preliminary Phase 1 Results for BHV-1530
BHVN Biohaven Ltd
$13.65 +5.81%
View chart & analysis → - 1Biohaven announced preliminary Phase 1 results for BHV-1530 on November 19, 2026.
- 2Among evaluable patients with active FGFR3 mutations treated with at least 3.3 mg/kg of BHV-1530, 6 patients achieved a partial response, representing a 60% partial response rate.
- 3As of the data cutoff on October 19, 2026, no treatment-related serious adverse events or deaths were reported among the 30 patients treated by Biohaven.
So what's the key point?
Biohaven shared early results from testing its new drug in people. 60% of patients saw an effect, and there were no serious side effects or deaths.
Source InvestorsHub +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.